קלרידקס

Land: Israel

Sprache: Hebräisch

Quelle: Ministry of Health

Wirkstoff:

CLARITHROMYCIN

Verfügbar ab:

DEXCEL LTD, ISRAEL

ATC-Code:

J01FA09

Darreichungsform:

קפליות

Zusammensetzung:

CLARITHROMYCIN 250 MG

Verabreichungsweg:

פומי

Verschreibungstyp:

מרשם נדרש

Hergestellt von:

DEXCEL LTD, ISRAEL

Therapiegruppe:

CLARITHROMYCIN

Therapiebereich:

CLARITHROMYCIN

Anwendungsgebiete:

Klaridex is indicated in the treatment of infections caused by one or more susceptible organisms. Indications include: Lower respiratory tract infections, for example, acute and chronic bronchitis and pneumonia. Upper respiratory tract infections, for example, sinusitis and pharyngitis. Klaridex is appropriate for initial therapy in community acquired respiratory infections and has been shown to be active in vitro against common and atypical respiratory pathogens as listed in the microbiology section. Klaridex is also indicated in skin and soft tissue infections of mild to moderate severity. Klaridex is also indicated in combination with proton pump inhibitor for the eradication of H. Pylori in patients with proven duodenal ulcer. Treatment of Mycobacterium Avium Complex infection in AIDS patients.

Berechtigungsdatum:

2014-05-31